Vaccines pp 161-171 | Cite as

Characterization of Immune Responses Elicited by an Experimental Facilitated-DNA Vaccine for Human Immunodeficiency Virus Type-1 (HIV-1)

  • M. J. Newman
  • L. Cooney
  • R. Carrano
  • J. Boyer
  • W. V. Williams
  • B. Wang
  • D. B. Weiner
Part of the Nato Science Series book series (NSSA, volume 282)


Vaccination has proved to be among the most successful methods developed for protecting humans and domestic animals from infectious diseases. Vaccines operate by inducing immune responses in the host that limit and ultimately clear infections; they typically do not prevent infections from occurring. Vaccine efficacy is therefore, dependent on the induction of appropriate types of immune responses and on the establishment of immunological memory.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Simian Immunodeficiency Virus Subunit Vaccine Major Histocompatibility Complex Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alving, C.R., Detrick, B., Richards, R.L., Lewis, M.G., Shafferman, A. and Eddy, G.A., 1993, Novel adjuvant strategies for experimental malaria and AIDS vaccines,Ann.NY.Acad.Sci., 690:265PubMedCrossRefGoogle Scholar
  2. Braciale, T.J., Morrison, L.A., Sweetser, M.T., Sambrook, J., Gething, M.J. and Braciale, V.L., 1987, Antigen presentation pathways to class I and class II MHC restricted T lymphocytes,Immunol.Rev., 98:95PubMedCrossRefGoogle Scholar
  3. Burke, D.S., 1992, Human HIV vaccine trials:Does antibody-dependent enhancement pose a genuine risk,Perspect.Biol.Med., 35:511PubMedGoogle Scholar
  4. Cooney, E.L., Collier, A.C., Greenberg, P.D., Coombs, R.W., Zarling, J., Arditti, D.E., Hoffman, M.C., Hu, S.L. and Corey, L, 1991, Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein,Lancet, 337:567PubMedCrossRefGoogle Scholar
  5. Cooney, E.L., McElrath, M.J., Corey, L., Hu., S.-L., Collier, A.C., Arditti, D., Hoffman, M., Coombs, R.W., Smith, G.E., Greenberg, P.D., 1993, Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein,Proc.Natl.Acad.Sci, USA, 90:1882PubMedCrossRefGoogle Scholar
  6. Daniel, M.D., Kirchhooff, F., Czajak, S.C., Sehgal, P.K. and Desrosiers, R.C., 1992, Protective effects of a live attenuated SIV vaccine with a deletion in thenefgene,Science, 258:1938PubMedCrossRefGoogle Scholar
  7. Desrosiers, R.C., 1994, Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine,AIDS Res.Hum.Retroviruses, 10:331PubMedCrossRefGoogle Scholar
  8. Eaton, A.M., Ugen, K., Weiner, D.B., Wildes, T. and Levy, J.A., 1994, An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement,AIDS Res.Hum.Retroviruses, 10:13PubMedCrossRefGoogle Scholar
  9. Fynan, E.F., Webster, R.G., Fuller, D.H., Haynes, J.R., Santoro, J.C. and Robinson, H.L., 1993, DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations,Proc.Natl.Acad.Sci.USA, 90:11478PubMedCrossRefGoogle Scholar
  10. Gotch, F.M., Hovell, R., Delchambre, M., Silvera, P. and McMichael, A.J., 1991, Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus,AIDS, 5:317PubMedCrossRefGoogle Scholar
  11. Graham, B.S., Belshe, R.B., Clements, M.L., Dolin, R., Corey, L, Wright, P.F., Gorse, G.J., Midthun, K., Keefer, M.C., Roberts, N.J. Jr., Schwartz, D.H., Agosti, J.M., Fernie, B.F., Stablein, D.M., Montefiori, D.C., Lambert, J.S., Hu, S.-L., Esterlitz, J.R., Lawrence, D.N., Koff, W.C. and AIDS Vaccine Clinical Trials Network, 1992, Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gpl60 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial,J.Infect.Dis., 166:244PubMedCrossRefGoogle Scholar
  12. Graham, B.S., Matthews, T.J., Belshe, R.B., Clements, M.L., Dolin, R., Wright, P.F., Gorse, G.J., Schwartz, D.H., Keefer, M.C., Bolognesi, D.P., Corey, L., Stablein, D.M., Esterliz, J.R., Hu, S.-L., Smith, G.E., Fast, P.E., Koff, W.C. and NIAID AIDS Vaccine Clin Trials Network, 1993, Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with gpl60 in vaccinia-naive adults,J.Infect.Dis., 167:533PubMedCrossRefGoogle Scholar
  13. Jiao, S., Williams, P., Berg, R., Hodgeman, B., Liu, B., Repetto, G. and Wolff, J., 1992, Direct gene transfer into nonhuman primate myofibersin vivo,Human Gene Therapy, 3:21PubMedCrossRefGoogle Scholar
  14. Kent, S.J., Stallard, V., Corey, L., Hu., S.-L., Morton, W.R., Gritz, L., Panicalli, D.L., Greenberg, P.D., 1994, Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses,AIDS Res.Hum.Retroviruses, 10:551PubMedCrossRefGoogle Scholar
  15. Kliks, S.C., Shioda, T., Haigwood, N.L. and Levy, J.A., 1993, V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1,Proc.Natl.Acad.Sci. USA, 90:11518PubMedCrossRefGoogle Scholar
  16. Mascola, JR., Mathieson, B.J., Zack, P.M., Walker, M.C., Halstead, S.B. and Burke, D.S., 1993, Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials,AIDS Res.Hum.Retroviruses, 9:1175PubMedCrossRefGoogle Scholar
  17. McElrath, M.J., Corey, L., Berger, D., Hoffman, M.C., Klucking, S., Dragavon, J., Peterson, E. and Greenberg, P.D., 1994, Immune responses elicited by recombinant vaccinia- human immunodeficiency virus (HIV) envelope and HIV envelope protein:Analysis of the durability of responses and effect of repeated boosting,J.Infect.Dis., 169:41PubMedCrossRefGoogle Scholar
  18. McGraw, T.P., Vowels, B.R., Gershwin, M.E. and Gardner, M.B., 1990, Cellular immune response of SIV-infected rhesus macaques,J.Med.Primatol., 19:177PubMedGoogle Scholar
  19. Miller, M.D., Gould-Fogerite, S., Shen, L., Woods, R.M., Koening, S., Mannino, R.J. and Letvin, N.L., 1991, Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes,J.Exp.Med., 176:1739CrossRefGoogle Scholar
  20. Miller, M.D., Lord, C.I., Stallard, V., Mazzara, G.P. and Letvin, N.L., 1990, Thegagspecific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques,J.Immunol., 144:122PubMedGoogle Scholar
  21. Morrison, L.A., Lukacher, A.E., Braciale, V.L., Fan, D.P. and Braciale, T.J., 1986, Differences in antigen presentation to MHC class I and class II restricted influenza virus specific cytolytic T lymphocyte clones,J.Exp.Med., 163:903PubMedCrossRefGoogle Scholar
  22. Munroe, K.J., Anderson, C.A., Wu, J.-Y., Wyand, M.S., Newman, G.W., and Newman, M.J., 1994, Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 viral peptides to nonhuman primate lymphocytes in proliferation and cytotoxic T-lymphoeyte assays,Clin.Diag.Lab.Immunol., 1:283Google Scholar
  23. Neefjes, J.J. and Momburg, F., 1994, Cell biology of antigen presentation,Curr.Opin.Immunol., 5:27CrossRefGoogle Scholar
  24. Newman, M.J., Wu, J.Y., Coughlin, R.T., Murphy, C.I., Seals, J.R., Wyard, M.S. and Kensil, C.R., 1992, Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates,AIDS Res.Hum.Retroviruses, 8:1413PubMedGoogle Scholar
  25. Plotkin, S.A. and Mortimer, E.A., eds., 1988,Vaccines, W.B. Saunders Co., PhiladelphiaGoogle Scholar
  26. Powell, M.F., Newman, M.J., eds., 1995, Vaccine Design: The Adjuvant and Subunit Approach, Plenum Publishing Co., New YorkGoogle Scholar
  27. Shen, L., Zheng, W.C., Miller, M.D., Stallard, V., Mazzara, G.P., Panicalli, D.L. and Letvin, N.L., 1991, Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes,Science, 252:440PubMedCrossRefGoogle Scholar
  28. Ulmer, J.B., Donnelly, J., Parker, S.E., Rhodes, G.H., Feigner, P.L., Dwarki, V.L., Gromkowski, S.H., Deck, R., Devitt, C.M., Friedman, A., Hawe, L.A., Leander, K.R., Marinez, D., Perry, H., Shiver, J.W., Montgomery, D. and Liu, M.A., 1993, Heterologous protection against influenza by injection of DNA encoding a viral protein,Science, 259:1745PubMedCrossRefGoogle Scholar
  29. Vowels, B.R., Gershwin, M.E., Gardner, M.B., Ahmed-Ansari, A. and McGraw, T.P., 1989, Characterization of simian immunodeficiency virus-specific T-cell-mediated cytotoxic responses of infected rhesus macaques,AIDS, 3:785PubMedCrossRefGoogle Scholar
  30. Wang, B., Boyer, J., Srikantan, V., Coney, L., Carrano, R., Phan, C., Merva, M., Dang, K., Agadjanan, M., Gilbert, L., Ugen, K.E., Williams, W.V. and Weiner, D.B., 1993a, DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates,DNA and Cell Biol., 12:799CrossRefGoogle Scholar
  31. Wang, B., Ugen, K.E., Srikantan, V., Agadjanyan, M.B., Dang, K., Refaeli, Y., Sato., A.I., Boyer, J., Williams, W.V., Weiner, D.B., 1993b, Gene inoculation generates immune responses against human immunodeficiency virus type 1,Proc.Natl.Acad.Sci USA, 90:4156PubMedCrossRefGoogle Scholar
  32. Wu, J.-Y., Gardner, B.H., Murphy, C.I., Seals, J.R., Kensil, C.R., Recchia, J., Beltz, G.A., Newman, G.W. and Newman, M.J., 1992, Saponin adjuvant enhancement of antigen- specific immune responses to an experimental HIV-1 vaccine,J.Immunol., 148:1519PubMedGoogle Scholar
  33. Yamamoto, H., Miller, M.Q., Tsubota, H., Watkins, D.L, Mazzara, G.P., Stallard, V., Panicalli, D.L., Aldovini, A., Young, R.A. and Letvin, N.L., 1990, Studies of cloned simian immunodeficiency virus-specific T lymphocytesgag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity,J.Immunol., 144:3385PubMedGoogle Scholar
  34. Yasutomi, Y., Koenig, S., Haun, S.S., Stover, C.K., Jackson, R.K., Conard, P., Conley, A.J., Emini, E.A., Fuerst, T.T. and Letvin, N.L., 1993, Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys,J.Immunol., 150:3101PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • M. J. Newman
    • 1
  • L. Cooney
    • 2
  • R. Carrano
    • 2
  • J. Boyer
    • 3
  • W. V. Williams
    • 4
    • 5
  • B. Wang
    • 3
    • 5
  • D. B. Weiner
    • 3
    • 5
  1. 1.Vaxcel, IncNorcrossUSA
  2. 2.Appolon IncMalvernUSA
  3. 3.BRB-1, Dept of PathologyUniv. of Pennsylvania School of MedicineUSA
  4. 4.Dept of MedicineUniv. of Pennsylvania School of MedicineUSA
  5. 5.Institute for Biotechnology and Advanced Molecular MedicineUniv. of Pennsylvania School of MedicineUSA

Personalised recommendations